For a company that badly needed some good news, Lexicon Pharmaceuticals' (LXRX) announcement of a settlement with now-former partner Sanofi (SNY)
for its Zynquista SGLT-1/2 inhibitor is a welcome development. While
the settlement, which returns full rights to the drug back to Lexicon
and includes a significant cash payment, is not a home run for the
company, it is at least a meaningful improvement over a protracted legal
fight with Sanofi, and the company can now look to secure a new
marketing partner.
The good news for Lexicon is that
the Sanofi deal still resulted in a European approval for Type 1
diabetes and a data package that will support filings for Type 2
diabetes in both the U.S. and Europe. The bad news is that further
funding will be necessary to finish all of the Zynquista studies,
Lexicon absolutely needs a partner to market the drug, and the company
is still looking at an uphill climb to gain market share with a drug
that doesn’t look particularly differentiated in Type 2 diabetes at this
point.
Read the full article here:
Lexicon Gets Some Clarity And Cash For Its Zynquista Diabetes Program
No comments:
Post a Comment